OMA Guidelines Bundle

Abbreviations ACE, angiotensin-converting enzyme; ACG, American College of Gastroenterology; ADHD, attention-deficit hyperactivity disorder; ARB, angiotensin receptor blockers; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; BNP, brain natriuretic peptide; CAD, coronary artery disease; CHF, coronary heart disease; CKM, cardiovascular-kidney-metabolic syndrome; CSF, cerebrospinal fluid; CT, computed tomography; CVA, cerebrovascular accident; CVD, cardiovascular disease; FDA, US Food and Drug Administration; FFA, free fatty acids; FSGS, focal segmental glomerulosclerosis; GERD, gastroesophageal reflux disease; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; GLP-1 RA, glucagon-like peptide 1 receptor agonist; H2FPEF, The Heavy, Hypertensive, Atrial fibrillation, Pulmonary hypertension, Elderly, Filling pressure Heavy Hypertensive Atrial Fibrillation Pulmonary Hypertension Elderly Filling Pressure; HCC, hepatocellular carcinoma; HCl, phentermine hydrochloride; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein-cholesterol HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; HPO, hypothalamic-pituitary-ovarian axis; HS, hidradenitis suppurativa; IBS, Irritable bowel syndrome; IL-6, interleukin 6; IIH, idiopathic intracranial hypertension; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein-cholesterol; MASH, metabolic dysfunction-associated steatohepatitis; LVEF, left ventricular ejection fraction; MASLD, metabolic dysfunction-associated steatotic liver disease; MRI, magnetic resonance imaging; NT, natriuretic peptide; NT-proBNP, N-terminal pro–B-type natriuretic peptide; OHS, obesity hypoventilation syndrome; OSA, obstructive sleep apnea; PCOS, polycystic ovary syndrome; PNPLA3, patatin- like phospholipase domain-containing 3; PPIs, proton pump inhibitors; PSA, prostate-specific antigen; RAAS, renin-angiotensin-aldosterone system; SCFE, slipped capital femoral epiphysis; SGLT2, sodium-glucose cotransporter 2; SNS, sympathetic nervous system; SSRI, selective serotonin reuptake inhibitors; T2DM, type 2 diabetes mellitus; TG, triglyceride; TM6SF2, transmembrane 6 superfamily member 2; TNF-α, tumor necrosis factor α; TSH, thyroid-stimulating hormone; TyG, triglyceride-glucose; USPSTF, United States Preventive Services Task Force; VLDL, very low-density lipoprotein Source Tondt J, Orr M, Damian A, Magee J, Okubo N, Manalac R, Othman A, Karjoo S, Rajpal A, Hooper J, Busse M, Copeland P, Corrado R, Jain S, Bowlin S, George Jr T, Frederiksen K, Pennings N. Obesity Algorithm Slides, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2026. https:// obesitymedicine.org/resources/obesity-algorithm/. (Accessed = March 2026) 1258 Upsala Rd Sanford, FL 32771 TEL: 407.878.7606 Copyright © 2026 All rights reserved Obesity Medicine Association 7173 S. Havana St #600–130 Centennial, CO 80112 TEL: 303.770.2526 OMAOBEAD03263a Disclaimer is resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers aer consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary.

• Cover